Related by context. All words. (Click for frequent words.) 77 Gets FDA Clearance 76 Initiates Clinical 75 Initiates Enrollment 75 Initiates Clinical Trial 74 Completes Patient Enrollment 74 Files IND 73 Receives Approvable Letter 73 Submits Response 73 Reveals Positive 73 Enrolls First 73 Initiates Phase II 73 Submits NDA 72 Begins Dosing 72 Initiates Phase III 72 Presents Positive 72 Completes Enrollment 72 Submits IND 72 Submits Biologics License Application 72 Announces FDA Clearance 71 Extends Collaboration 71 Presents Positive Preclinical 71 Announce License Agreement 71 Demonstrates Significant 71 Therapeutic Competitors Companies 71 Receives Orphan Drug Designation 71 IG HCR ;) CO 71 Files Shelf Registration Statement 71 Announce Collaboration Agreement 71 Initiates Phase 2b 71 Licenses Novel 71 Amends Agreement 70 Presents Preclinical Data 70 Receives CE Marking 70 Reports Preclinical Data 70 Receives Milestone Payment 70 Successfully Completes Phase 70 Receive Milestone Payment 70 Pivotal Study 70 Psoriasis Drug 70 Welcomes Analyst Initiation 70 Earns Milestone Payment 70 FDA Approvals 69 Initiate Clinical Trial 69 Submits Supplemental 69 Present Preclinical Data 69 BioSante Pharmaceuticals Announces 69 Becton Dickinson BD 69 Inc. NASDAQ EVVV 69 FDA Clears 69 Licenses Patents 69 Earnings Postmortem 69 Cites Positive 69 Phase IIb Clinical Trial 69 Files Investigational 69 Completes Buyout 69 Q1 Profit Decreases 69 Commences Phase 69 Inc Therapeutic Competitors 69 Presents Preclinical 68 Initiates Dosing 68 Submits Application 68 Launches Generic Version 68 Jumps Higher 68 Begins Shipment 68 Beats Raises Guidance 68 Successfully Completes Tender Offer 68 Meets Primary Endpoint 68 FDA Okays 68 Receives Subpoena 68 Q4 Profit Decreases 68 Severe Sepsis 68 Achieves Primary Endpoint 68 PROMUS R 68 Files Patent Application 68 Receives Favorable 68 Drug Fails 68 Pivotal Clinical Trial 68 initiated Phase Ib 68 Q2 Loss Narrows 68 Announces Discontinuation 68 Initiates Clinical Trials 68 Receives Positive Opinion 68 Sinks Lower 68 Q3 Adj 67 Cypher Sirolimus 67 Completes Dosing 67 Q1 Loss Narrows 67 Therapeutic Competitors companiesandmarkets.com adEgemonye 67 Corp BSX 67 Significantly Reduces 67 Receives Complete Response 67 Q2 Adj 67 Partnering Agreements 67 Announces Licensing Agreement 67 Restructures Operations 67 Q1 Adj 67 Arthritis Drug 67 Announces License Agreement 67 Receives Clearance 67 Completes Tender Offer 67 REG1 Anticoagulation System 67 Announces Poster Presentations 67 Phase 2b Clinical Trial 67 Awarded Patents 67 Lupus Drug 67 Receives FDA Clearance 67 Announces Tentative Approval 67 Clinical Trial Evaluating 67 Xcytrin R 67 Microwave Ablation System 67 R MSCRAMM 67 Receives Orphan Drug 67 Receives Unsolicited 67 Investigational Compound 67 Q2 Loss Widens 67 Receives Fast Track 67 visit http:/www.mannkindcorp.com 67 Announce Licensing Agreement 67 Completes Merger With 67 Settles Patent Dispute 66 FDA Approves Expanded 66 Prolongs Survival 66 Explores Strategic Alternatives 66 Inhaled Insulin 66 Sign License Agreement 66 Regains NASDAQ 66 Q3 Loss Narrows 66 Demonstrates Sustained 66 First Patient Enrolled 66 Receives Tentative Approval 66 Patient Enrollment 66 Announce Merger Agreement 66 Receives NASDAQ 66 Voluntarily Withdraws 66 Therapeutic Competitors Report 66 Bearish MACD 66 Q4 Loss Narrows 66 HCV Protease Inhibitor 66 proprietary radiolabeled monoclonal 66 Announces Initiation 66 Obtains CE Mark 66 JAK2 Inhibitor 66 PROMUS TM 66 Files Shelf Registration 66 Investigational Oral 66 Demonstrates Positive 66 Q2 Profit Decreases 66 please visit http:/www.vandapharma.com 66 Introduces Expanded 66 Regains Full 66 Rheumatoid Arthritis Drug 66 FDA Accepts 66 PRN FDA Approves 66 please visit www.dyax.com 66 Stays Neutral 66 Retains CCG Investor Relations 66 Sign Licensing Agreement 66 PharmaVitae Profile 66 Attracting Bullish Investors 66 SVP Exercises Options 66 Announces Divestiture 66 * vwd PRN 66 Webcast Presentations 66 Obtains Approval 66 IND Filing 66 Collaborators Publish 66 please visit www.epocrates.com 66 AUDIO PROVIDED BY 66 please visit http:/www.atherogenics.com 66 Provides Guidance 66 Identifies Potential 66 Lung Cancer Drug 66 Updates Guidance 66 Q3 Loss Widens 66 Pivotal Trial 66 NASDAQ ADLR 66 Enters Definitive Agreement 65 Announces Presentation 65 Gets Clearance 65 Corp. ADLR 65 Taglich Brothers Initiates Coverage 65 Phase III Trial 65 Strengthens Position 65 Successfully Completes Acquisition 65 Achieves Positive 65 SIX RO ROG 65 Receives Approval From 65 Vaccine Adjuvant 65 Naglazyme R 65 Receives SFDA Approval 65 Milestone Payment 65 Strengthens Balance Sheet 65 hoFH 65 Genentech sanofi aventis 65 Boosts Buyback 65 NDA Submission 65 Commences Phase III 65 Web Site http:/www.cryolife.com 65 Q4 Loss Widens 65 Improves Survival 65 Phase III Clinical Trial 65 Clinical Trial Results 65 Pivotal Phase III 65 NICE Recommends 65 Voluntarily Withdraw 65 ILEX Oncology 65 NASDAQ ANGO 65 please visit http:/www.astrazeneca-us.com 65 Receives Notice Related 65 Receives Anticipated 65 Shows Efficacy 65 Receives Tentative FDA 65 Potelligent Technology 65 visit www.noven.com 65 Terminate Merger Agreement 65 3Q Loss Narrows 65 Develop Novel 65 Oncology Compounds 65 Embolic Protection 65 Appoints Seasoned 65 Momenta Pharmaceuticals MNTA 65 Initiate Phase 65 TM Aganocide 65 Q2 Profit Surges 65 Receives Notification From 65 Achieves Record Sales 65 Consulting Fees Honoraria 65 Integra Lifesciences 65 Reversal Soon 65 please visit http:/www.sunesis.com 65 please visit www.middlebrookpharma.com 65 Explore Strategic Alternatives 65 Carotid Artery Stenting 65 Issues Guidance 65 please visit www.astrazeneca.com 65 Board Authorizes 65 Q1 Profit Soars 65 Exec Exercises Options 65 Regains Nasdaq 65 Significantly Increases 65 Shareholders Approve Merger Agreement 65 COLAZAL R 65 Cholesterol Drug 65 Drug Shows Promise 64 Shareholders Approve Acquisition 64 Initiates Voluntary 64 TRACON Pharmaceuticals 64 Renews Relationship 64 Receives CE 64 SWOT Analysis Aarkstore Enterprise 64 Advanced Melanoma 64 novel oral anticoagulant 64 Inc AMGN AMGN 64 Receives Approvals 64 markets HP Acthar 64 Emphasys Medical 64 Board Unanimously Rejects 64 Announce Definitive Agreement 64 Reacquires 64 Receives Favorable Ruling 64 Successfully Concludes 64 Achieves Record Quarterly 64 Generic Versions 64 OTC Zegerid 64 Enters Oversold Territory 64 Completes Previously Announced 64 Q4 Profit Climbs 64 Collaborators Present 64 RDYN 64 Announces Organizational Changes 64 Dealmaking Profile 64 Penwest Pharma 64 PROVENGE ® 64 website www.celsion.com 64 Bullish Average Crossover 64 NASDAQ VRUS 64 First Patient Treated 64 Expands Scientific Advisory 64 Improves Outcomes 64 visit www.genenews.com 64 Phase IIb Trial 64 Beats Estimates Analyst Blog 64 TKPHF 64 KAI Pharmaceuticals 64 BioDelivery Sciences Announces 64 Matrix Phase 2b 64 Granted Orphan Drug 64 ALPMF 64 Secures Financing 64 Bullish Engulfing Formed 64 Settle Patent Litigation 64 Endures Analyst Downgrade 64 SPRYCEL ® 64 Receives URAC Accreditation 64 Canaccord Genuity Maintains Hold 64 Completes Divestiture 64 Ondansetron Orally Disintegrating Tablets 64 Investigational Treatment 64 Demonstrates Potential 64 Stockholders Approve Acquisition 64 Q4 Adj 64 Liberte TM 64 Submits Investigational 64 Sirolimus eluting 64 Synvisc ONE 64 Initiate Phase II 64 Announces Adjournment 64 Single Dose 64 OvaRex R 64 acetonide FA 64 Phase 2a Trial 64 Posts Wider Loss 64 FDA Approves Generic 64 Appoints Experienced 64 visit http:/www.PAREXEL.com 64 Reschedules Fourth Quarter 63 Heart Transplant Recipients 63 Commercialize Novel 63 Osteoporosis Drug 63 Data Suggest 63 Revises FY# Outlook 63 Announces Publication 63 Combination REOLYSIN R 63 Pharmacueticals 63 Ms. Katen 63 Achieves Milestone 63 oncolytic virus therapies 63 Remains Neutral 63 Insulin Nasal Spray 63 Inc CYBX 63 Sets Record Date 63 Confirms Commitment 63 Enzon Pharmaceuticals Inc 63 Nasdaq ALXA 63 Schizophrenia Treatment 63 www.vivus.com 63 Hsp# Inhibitor 63 includes Dideco CarboMedics 63 Therapeutic Competitors 63 NASDAQ DIGE 63 visit www.FRX.com 63 IND Application 63 AFREZZA TM 63 Inc POZN 63 Partnering Guide 63 Receives Patent 63 Significantly Improved 63 NASDAQ IDIX 63 Drug Candidate 63 Expanded Indication 63 Sets Second Quarter 63 Drug Eluting Coronary Stent 63 RapidMist 63 pharmacogenomic translational research 63 Transdermal Patch 63 Phase 2b Trial 63 please visit www.medicinova.com 63 Postpones Annual Meeting 63 EMD Biosciences Inc. 63 Aloxi ® 63 Obtains License 63 website http:/www.celsion.com 63 Provides Update Regarding 63 WeissComm Partners +#-#-#-# 63 Stockholders Approve Merger 63 Significantly Improves 63 Catalyst Biosciences 63 Cyclacel Pharmaceuticals 63 technology visit http:/www.genmab.com 63 Announces Postponement 63 Pegloticase 63 Diabetic Foot Ulcer 63 Nasdaq IDIX 63 Obtains Exclusive License 63 Gets Subpoena 63 MOVIPREP R 63 Signs Merger Agreement 63 Receives Stockholder Approval 63 Nasdaq SPNC 63 Immunomedics Announces 63 EVP Exercises Options 63 Receives Deficiency Letter 63 NewsBite Downgrade Puts Pressure 63 CNS Therapeutics 63 Hedgehog Pathway Inhibitor 63 Announces Consummation 63 proprietary intravenous formulation 63 successfully commercialize Iluvien 63 Taro Receives 63 Phase III Trials 63 FDA APPROVES 63 Expands Scope 63 Cardiometabolic 63 Prostate Cancer Vaccine 63 Finalizes Purchase 63 Nasdaq PGNX 63 Upcoming Conferences 63 CEO Exercises Options 63 VNS Therapy TM 63 Recurrent Glioblastoma 63 Competitor Report 63 please visit www.eisai.com 63 Posts Wider 63 Antibody Drug Conjugate 63 Risperidone Oral Solution 63 Shows Promising 63 Cytori Therapeutics CYTX 63 Gout Drug 63 novel emulsion formulation 63 Begins Tender Offer 63 PF # [002] 63 visit http:/www.neogenomics.org 63 Phase IIa Clinical Trial 63 NPS Pharma 63 Vitrasert R 63 TELINTRA R 63 FY# Loss Narrows 63 Receives URAC 63 OMNARIS Nasal Spray 63 Reports Positive 63 DepoCyt 63 AstraZeneca AZN.L 行情 63 Webcast Discussion 63 Boosts Quarterly Dividend 63 Announces Favorable 63 Exherin 63 Initiates Phase 63 Metabasis Therapeutics 63 hyaluronidase enzyme 63 ESTRASORB ® 63 Withdraws Application 63 EVP Sells 63 Patients Treated With 63 Inc. Attracting Bullish 63 Proven Effective 63 PROFILE CO 63 Backs FY# Outlook 63 NASDAQ BMRN 63 Nasdaq CYTX 62 manufactures minimally invasive 62 BUPHENYL R 62 R agalsidase beta 62 Enhanze 62 Drew Fromkin President 62 Webcast Annual Meeting 62 PHRM 62 Inks Licensing Deal 62 Announces Recapitalization 62 1Q Profit Tumbles 62 NASDAQ ACOR 62 Phase III Pivotal 62 CyDex Pharmaceuticals 62 SUTENT ® 62 AMITIZA ® 62 Vascular Wrap TM 62 Coverage Initiated 62 Epilepsy Drug 62 TM Drug Eluting 62 Announce Initiation 62 Inc. NASDAQ CVTX 62 visit www.targanta.com 62 Mylan Receives Approval 62 NASDAQ SCRX specialty 62 Settles Patent Litigation 62 please visit www.abraxane.com 62 SWOT Analysis http:/www.companiesandmarkets.com aJEH MacDonald 62 Alnylam Nasdaq ALNY 62 Puts Sold 62 Inc. Nasdaq AMGN 62 Reduces Risk 62 Regains Compliance With 62 THALOMID 62 Pulmonary Arterial Hypertension 62 Package Insert 62 Novel Oral 62 PFIZER INC. 62 VIVUS Announces 62 NASDAQ ONXX 62 Schizophrenia Drug 62 Nasdaq AVNC 62 NASDAQ BDSI 62 Commence Phase 62 Signs Licensing Agreement 62 Successfully Integrates 62 STARFlex R 62 Corp. Nasdaq GENZ 62 Regeneron Pharma 62 BIOTECHNOLOGY SOURCE 62 Receives Clearance From 62 Regenerative Cell 62 Receives ISO #:# [002] 62 Preclinical Data 62 Commercializes 62 Biomarker Study 62 Sunesis Pharma 62 Broadens Its 62 Cardiology Rhythm 62 NovoNordisk 62 Nasdaq KNSY 62 Implantable Defibrillators 62 INDICATED LOWER 62 Platinum Chromium 62 HOSPIRA 62 Metabolic Disorder 62 Inc. NASDAQ NOVC 62 Confirms Efficacy 62 Completes Reorganization 62 delivers fluocinolone acetonide FA 62 Unveils Revolutionary 62 Obtains FDA 62 candidate TNFerade biologic 62 Milestone Payment From 62 Migraine Drug 62 Teva Provides Update 62 Genentech Wyeth Pharmaceuticals 62 Amorcyte 62 azilsartan medoxomil 62 Selects BoardVantage 62 #-# Full Text 62 Crofelemer budesonide foam 62 mesylate tablets approved 62 Raptiva R 62 Pivotal Phase 62 oral salmon calcitonin 62 Announces Successful Completion 62 Recommends Approval 62 ALN VSP Phase 62 Small Molecule Drug 62 Signs Purchase Agreement 62 Receives Commitment 62 Dale Pfost 62 Intravitreal 62 Deliver Presentation 62 Abstract Accepted 62 Signs License Agreement 62 Xytis 62 submitted Biologics License 62 Braintree Laboratories 62 epoetin zeta 62 Receives Conditional 62 Inc. OTCBB SPRX 62 AcelRx Pharmaceuticals 62 Pending Acquisition 62 Corp GENZ 62 Tramiprosate ALZHEMED TM 62 Receives Delisting Notice 62 Atelvia 62 liver resection surgeries 62 KV.A 62 Adjourns Special Meeting 62 Closes Merger 62 Announces Repurchase 62 FY# Loss Widens 62 Hold Third Quarter 62 NASDAQ ANGO leading 62 Acquire Privately Held 62 Meritage Pharma 62 Enters Into Licensing Agreement 62 Bearish Pressure Building 62 Veronate R 62 M# rationally 62 albiglutide 62 Carotid Stent 62 Inc EXEL 62 BOSTON SCIENTIFIC 62 Hematide ™ peginesatide 62 Smith Kline Beecham 62 Subsidiaries Consolidated Statement 62 TM Everolimus Eluting 62 XenoPort NASDAQ XNPT 62 JAK Inhibitor 62 Subsidiary Enters 62 Guides FY# Quick Facts 62 Announces Cancellation 62 Anti Infective 62 please visit http:/www.supergen.com 62 Hires Experienced 62 Dramatically Increases 62 Rinat Neuroscience 62 Signs Definitive Merger Agreement 62 Adjunctive Therapy 62 SYCREST 62 Inc FRX 62 CRMD# 62 Frozen Shoulder syndrome 62 AIMM trial 62 TAXUS Element Stent System 62 Oral Calcitonin 62 Receives Delisting Notification 62 Generic Version Of 62 Nasdaq CADX 62 Extends Tender Offer 62 Expands Commitment 62 Myocet 62 Adverse Event 62 programs visit http:/www.bionovo.com 62 Tissue Repair 62 Gendux AB 62 Extends Expiration Date 62 subsidiaries visit http:/www.apricusbio.com 62 Immunosuppressant 62 Anemia Drug 62 Nipent R 62 Aryplase 62 Clinical Trial Enrollment 62 ONCY 62 NDQ 62 Idenix Novartis 62 SinuNase ™ 62 Exploring Strategic Alternatives 62 Investigational Drug 62 Drug Coated Stent 62 Inc SPPI 62 TriPath Oncology 62 INSPIRE Trial Phase III 62 Provides Shareholder 62 molecular imaging radiopharmaceutical 62 Guidelines Issued 62 Receives Positive 62 Dry Powder Inhaler 62 Novartis Novo Nordisk 62 including eniluracil ADH 62 Flamel Technologies Announces 62 Sees Continued Growth 62 Bacterin develops manufactures 62 Namenda Memantine HCl 62 Chugai Pharma 62 Inc NGSX 62 Report companiesandmarkets.com adds 62 Custom NX R 62 Q2 Profit Climbs 61 ParinGenix 61 Trubion Pharma 61 Demonstrates Commitment 61 NASDAQ ENMD 61 Bristol Myers Squibb Pravachol 61 Successfully Treats 61 midstage clinical 61 Restates Earnings 61 Holds Annual Meeting 61 GVAX ® 61 Alexza Pharma 61 Initiates Quarterly Dividend 61 Psivida 61 Reduces Mortality 61 Immunotherapeutic 61 Antimicrobial Coating 61 Nasdaq DVAX 61 Repliform 61 Sees Steady 61 Expands Capabilities 61 Shire plc SHPGY 61 ARIXTRA R 61 pediatric Crohn disease 61 Gamunex C 61 Restanza TM 61 Interferon Alpha 61 Amends Stockholder Rights 61 EZEM 61 Enters Into Collaboration 61 Cumulase 61 Rule Breakers pick 61 Files Annual Report 61 ENLIGHT 61 Efficacy Results 61 Inhaled Liposomal Ciprofloxacin 61 Reconfirms 61 Shows Promise Against 61 Bone Metastases 61 KAI Pharmaceuticals Inc. 61 Augment ™ 61 Molecular Diagnostic Test 61 Anti infective 61 http:/www.unigene.com 61 Milestone Payments 61 Resubmission 61 please visit www.abmc.com 61 Finalizes Acquisition 61 M.D. Joins 61 vapreotide acetate 61 For Undisclosed Terms 61 vinorelbine tartrate 61 Visit www.BASInc.com 61 Restate Earnings 61 Pivotal Trials 61 ARYX 61 Roche OTC RHHBY 61 Completes Debt Refinancing 61 Selenia Dimensions System 61 Stockholders Approve Merger Agreement 61 Vascular Graft 61 MarrowXpress 61 Nasdaq VNDA 61 MBRX 61 Bearish Speculation 61 GENR 61 Announce Expiration 61 Valera Pharmaceuticals 61 Patients Receiving 61 Protease Inhibitor 61 Angiox ® 61 Study Validates 61 NASDAQ ALXN 61 Inc CEPH 61 Zeneus 61 Signs Agreements 61 urethral bulking agent 61 Develop Next Generation 61 Corp EPCT 61 Bosutinib 61 Anticancer Drug 61 Bioresorbable 61 Central Venous Catheter 61 Testosterone Gel 61 Provides Comprehensive 61 Phase 1b Clinical Trial 61 Achieves ISO #:# Certification [002] 61 Nasdaq AVNR 61 Reports Receipt 61 Declares Dividend Quick Facts 61 Newly Diagnosed Multiple Myeloma 61 NASDAQ SPPI 61 Showed Significant 61 SinuNase TM 61 Transcept Pharmaceuticals 61 Awarded Qualifying Therapeutic 61 Personalized Immunotherapy 61 corticotropin injection 61 Plaque Psoriasis 61 Completes Recapitalization 61 CNS Disorders 61 Selective Electrochemical Tumor Ablation 61 Enters Into License Agreement 61 NGSX 61 plc ELN 61 Nicotine Vaccine 61 John F. Thero 61 Inc. NASDAQ ELGX 61 Q4 Profit Drops 61 Levoleucovorin 61 Nasdaq NPSP 61 Nasdaq IMGN 61 Wyeth Enbrel 61 Unveils Enhancements 61 Ltd Therapeutic Competitors 61 Moving Average Crossover Alert 61 Tibotec BVBA 61 ANGN 61 Declares Quarterly Dividends 61 suitablility 61 Study Evaluating 61 Previously Treated 61 2Q Loss Narrows 61 Peginterferon alfa 2b 61 TriCo Bancshares Announces 61 Canaccord Genuity Reiterates Buy 61 BRILINTA 61 Advanced Colorectal Cancer 61 Study Showed 61 Shingles Vaccine 61 CorVel Announces 61 Obtains Exclusive Rights 61 PhD RPh 61 Transcatheter 61 ZyStor Therapeutics Inc. 61 Ventricular Assist Devices 61 Zegerid OTC 61 Novel Compound 61 www.pharsight.com 61 REMINYL ® 61 FSE FME 61 Delivers Solid 61 INTERNATIONAL HOLDINGS INC. 61 Corp. BVF CN 61 Treatment Naïve 61 visit http:/www.gsk.com 61 Nasdaq ACHN 61 Announces Definitive Agreement 61 FDA Approves 61 Percutaneous Tibial Nerve Stimulation 61 Isis Pharma 61 Eluting Coronary Stent System 61 TAXUS Element Paclitaxel Eluting 61 Unveils Groundbreaking 61 Amend Merger Agreement 61 Surgical Mesh 61 Drug Eluting Stent System 61 Takeda Pharma 61 Vascular Disrupting Agent 61 Nasdaq ONXX 61 Antitumor Activity 61 Treatment Resistant 61 RELOVAIR ™ 61 Demonstrates Statistically Significant 61 ORADUR ® 61 oral picoplatin 61 NASDAQ PCYC 61 Inc. OTCBB ALRX 61 Personalized Genetic 61 ISTO Technologies 61 Closes Previously Announced 61 BrachySil TM 61 Nasdaq HALO 61 R lenalidomide 61 Declares Preferred 61 NASDAQ CGPI 61 Phase Ib IIa 61 LEUKINE 61 Combination Treatment 61 Unveils Enhanced 61 Avanir Pharma 61 OMAPRO ™ 61 Core Spinal 61 Increases Share Repurchase 61 http:/www.cephalon.com/ 61 NASDAQ MIPI 61 OTC BB PVCT 61 Vascular Grafts 61 Bayhill Therapeutics 61 Nasdaq ANPI 61 Nasdaq VRTX today 61 sterile lidocaine patch 61 Demonstrates Ability 61 Inc. OTCBB CYKN 61 Multiple Ascending Dose 61 Nasdaq PSTI 61 Guides FY# Update 61 Anti Tumor 61 Injectable Drug 61 NASDAQ BIOD 61 Nasdaq SGEN 61 Romiplostim 61 Registration Statement Declared Effective 61 deCODE AF TM 61 Restructures Debt 61 evaluating mipomersen 61 Sanofi NYSE SNY 61 NASDAQ CYTX 61 Inc. Nasdaq OXGN 61 Nancy Wysenski 61 Study Demonstrates 61 Evaluate Strategic Alternatives 61 Evoltra ® 61 t2cure GmbH 61 Randomized Clinical Trial 61 Plans Buyback 61 Patent Issued 61 3M Completes Acquisition 61 segment Biotest 61 Spinal Implants 61 LibiGel transdermal testosterone gel 61 NASDAQ MOGN 61 Co BMY 61 ficlatuzumab 61 Xanthus Pharmaceuticals Inc. 61 Crosses Above 61 Salix Pharmaceuticals Announces 61 Adjuvant Treatment 61 VentiRx Pharmaceuticals 61 Somatuline Depot 61 Achieves ISO # 61 NASDAQ PPDI 61 Aflibercept 61 Carbidopa Levodopa 61 Cypress Bioscience Inc 61 Terminates Contract 61 Drug Eluting Stent 61 Crit Rev 61 Aethlon Medical Releases 61 Differentiates 61 Xoma Ltd 61 Transcatheter Valve 61 Inhalation Solution 61 Significantly Reduced 61 NeutroSpec TM 61 PERSEUS clinical program 60 AMEX RGN 60 Endurant 60 Thewallstreetleader.com Profiles 60 Temodar ® 60 Completes Patient Enrolment 60 molecular chaperone regulation 60 GERD migraine headaches 60 Diastolic Heart Failure 60 pioglitazone hydrochloride 60 Morphine Sulfate 60 Warfarin Coumadin 60 MultiCell Technologies 60 Anticancer Agent 60 Implantable Device 60 FDA Clearance 60 Boxed Warnings 60 Liprotamase 60 ASX PGL 60 Frova ® 60 PDL BioPharma Announces 60 Syndax Pharmaceuticals Inc. 60 Study Evaluates 60 GetGoal Phase III 60 Xeloda ® 60 Reports Inducement Grants 60 Trastuzumab DM1 60 Clinical Trial Data 60 Targanta Therapeutics Corporation 60 Humira adalimumab 60 Long Term Efficacy 60 NexStent 60 Receives Regulatory Approvals 60 KRYSTEXXA TM pegloticase 60 XIAFLEX ® 60 Syntonix Pharmaceuticals 60 Regains Compliance 60 Nasdaq IPXL 60 Commenced Against 60 Kelly Luethje #-#-# 60 INVEGA TM 60 Vicriviroc 60 Conatus Pharmaceuticals 60 Alvine Pharmaceuticals 60 HP Acthar Gel repository 60 Reaches Tentative Settlement 60 sunitinib Sutent 60 Randomized Clinical Trials 60 Backs FY# 60 Millenium Pharmaceuticals 60 Disease Modifying 60 Spinal Fusion 60 PFE PFE 60 Tyrosine Kinase Inhibitor 60 HuMax TAC 60 DEB# 60 Pirespa 60 Nasdaq ADLR 60 Nasdaq CYCC Nasdaq CYCCP 60 Novel Therapeutic 60 Phase 2a Clinical Trial 60 Adopts Stockholder Rights 60 Settles Litigation 60 visit www.bioject.com 60 Detrol Detrol LA 60 Cholesterol Lowering Drug 60 Hematological Malignancies 60 Biotherapeutic 60 Aztreonam Lysine 60 Receives Regulatory 60 Unanimously Recommends Approval 60 Corporation GENZ 60 Reiterates FY# Outlook 60 J.P. Morgan Healthcare 60 NOVN 60 Cervical Dysplasia 60 SYN X 60 Generic Version 60 Corp. GERN 60 Reaches Profitability 60 HEPLISAV TM 60 Develops Novel 60 Cima Labs 60 SRDX 60 Receives Confirmation 60 Gemzar gemcitabine 60 Enhances User Experience 60 DYAX 60 doxercalciferol 60 PDUFA Date 60 Desvenlafaxine Succinate 60 TRANSDUR ® 60 treat chronic sinusitis 60 Calls Purchased 60 TSRX 60 Announce Early Termination 60 Amylin Pharma 60 Supplemental Biologics License Application 60 Provide Comprehensive 60 http:/www.sunesis.com 60 adalimumab Humira 60 Roche Boniva 60 Athena Neurosciences 60 Nasdaq PANC 60 topical gel formulation 60 OKs Buyback 60 Biggest laggers 60 Marketed Products 60 Small Molecule 60 PANVAC VF 60 CYTC 60 NASDAQ DSCO 60 Investor Relations website http:/investor.covidieConcepcion Tarlac 60 UGNE 60 Resolves Dispute 60 Axxion TM 60 Reveals Significant 60 Reiterates Strong 60 Dry Powder Inhalers 60 Nasdaq MITI 60 Oral Insulin 60 AVEO Pharmaceuticals 60 http:/www.pharmacopeia.com 60 Inc SEPR